- Home
- PEB vs PHVS Comparison
PEB vs PHVS Comparison
Compare PEB & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEB
- PHVS
- Stock Information
- Founded
- PEB 2009
- PHVS 2015
- Country
- PEB United States
- PHVS Switzerland
- Employees
- PEB N/A
- PHVS N/A
- Industry
- PEB Real Estate Investment Trusts
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- PEB Real Estate
- PHVS Health Care
- Exchange
- PEB Nasdaq
- PHVS Nasdaq
- Market Cap
- PEB 1.1B
- PHVS 909.5M
- IPO Year
- PEB 2009
- PHVS 2021
- Fundamental
- Price
- PEB $9.62
- PHVS $16.78
- Analyst Decision
- PEB Hold
- PHVS Buy
- Analyst Count
- PEB 6
- PHVS 6
- Target Price
- PEB $12.05
- PHVS $37.17
- AVG Volume (30 Days)
- PEB 2.1M
- PHVS 64.6K
- Earning Date
- PEB 07-23-2025
- PHVS 05-13-2025
- Dividend Yield
- PEB 0.42%
- PHVS N/A
- EPS Growth
- PEB N/A
- PHVS N/A
- EPS
- PEB N/A
- PHVS N/A
- Revenue
- PEB $1,459,506,000.00
- PHVS N/A
- Revenue This Year
- PEB $1.63
- PHVS N/A
- Revenue Next Year
- PEB $3.39
- PHVS N/A
- P/E Ratio
- PEB N/A
- PHVS N/A
- Revenue Growth
- PEB 2.19
- PHVS N/A
- 52 Week Low
- PEB $7.42
- PHVS $11.51
- 52 Week High
- PEB $15.12
- PHVS $25.50
- Technical
- Relative Strength Index (RSI)
- PEB 54.27
- PHVS 53.08
- Support Level
- PEB $8.80
- PHVS $15.91
- Resistance Level
- PEB $9.22
- PHVS $18.00
- Average True Range (ATR)
- PEB 0.29
- PHVS 0.86
- MACD
- PEB -0.00
- PHVS -0.03
- Stochastic Oscillator
- PEB 67.03
- PHVS 51.97
About PEB Pebblebrook Hotel Trust of Beneficial Interest
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.